One-on-One: TDD Talks to Paul Lizzul, MD, PhD, Chief Medical Officer, AnaptysBio
AnaptysBio is developing ANB032, an investigational B and T lymphocyte attenuator (BTLA) receptor agonist, for the treatment of atopic dermatitis (AD). The Company recently presented preclinical data at the American Academy of Dermatology’s (AAD) annual meeting in San Diego, CA. Paul Lizzul, MD, PhD, Chief Medical Officer of AnaptysBio, spoke with the Dermatology Digest about […]